CN100502854C - 绿原酸在制备抗糖尿病并发症的药中的应用 - Google Patents

绿原酸在制备抗糖尿病并发症的药中的应用 Download PDF

Info

Publication number
CN100502854C
CN100502854C CNB2007100513411A CN200710051341A CN100502854C CN 100502854 C CN100502854 C CN 100502854C CN B2007100513411 A CNB2007100513411 A CN B2007100513411A CN 200710051341 A CN200710051341 A CN 200710051341A CN 100502854 C CN100502854 C CN 100502854C
Authority
CN
China
Prior art keywords
chlorogenic acid
medicine
application
aldose reductase
diabetic complication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2007100513411A
Other languages
English (en)
Other versions
CN101002760A (zh
Inventor
丁虹
王莹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuhan University WHU
Original Assignee
Wuhan University WHU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuhan University WHU filed Critical Wuhan University WHU
Priority to CNB2007100513411A priority Critical patent/CN100502854C/zh
Publication of CN101002760A publication Critical patent/CN101002760A/zh
Application granted granted Critical
Publication of CN100502854C publication Critical patent/CN100502854C/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Abstract

本发明涉及绿原酸在制备抗糖尿病并发症的药中的应用。本发明可将绿原酸与药用载体和/或赋形剂制得药用组合物。所制得的药用组合物用于抑制醛糖还原酶活性,预防、治疗糖尿病并发症,具有疗效好,副作用少等优点。

Description

绿原酸在制备抗糖尿病并发症的药中的应用
技术领域
本发明涉及绿原酸的用途,尤其涉及在制药领域中的用途。
背景技术
糖尿病长期高血糖状态会对体内许多组织和器官产生危害,可引起糖尿病性肾脏、视网膜、神经等病变,其发病机制与多元醇途径中必需的限速酶——醛糖还原酶活性的升高关系密切,应用醛糖还原酶抑制剂可预防和治疗这些并发症。临床上已有较多醛糖还原酶抑制剂被应用,如索比尼尔、依泊斯它、多克斯等,但是因为毒副作用较大,限制了使用。因此,从我国传统中药中筛选毒副作用小、醛糖还原酶抑制作用强的药物是当务之急。
绿原酸chlorogenicacid,CGA,又名咖啡鞣酸,以金银花、杜仲中的含量较高,具有广泛的药理作用,如:心血管保护作用;抗诱变及抗癌作用;抗菌及抗病毒作用;降脂作用;抗白血病作用;免疫调节作用及降糖作用,国内外文献均未见有关绿原酸抑制醛糖还原酶活性的报道,本发明提供绿原酸作为一种新的醛糖还原酶抑制剂,用于治疗糖尿病并发症。
发明内容
本发明就是针对上述问题提供绿原酸在制备糖尿病并发症的药中的用途,用绿原酸制备醛糖还原酶抑制剂的药物对糖尿病并发症具有较好的疗效,且副作用少。
本发明提供的技术方案是:绿原酸在制备糖尿病并发症的药中的应用。
上述绿原酸可作为醛糖还原酶抑制剂在制备抗糖尿病并发症的药中的应用。
上述抗糖尿病并发症的药为有效剂量的绿原酸与药用载体和/或赋形剂的组合物。
上述抗糖尿病并发症的药可为口服制剂、注射剂或滴眼剂。
本发明可将绿原酸与药用载体和/或赋形剂制得药用组合物。所制得的药用组合物用于抑制醛糖还原酶活性,预防、治疗糖尿病并发症,具有疗效好,副作用少等优点。
附图说明
图1为绿原酸对醛糖还原酶抑制作用图;
图2为绿原酸对糖尿病鼠肾损伤的影响图。
具体实施方式
本发明通过以下实施例作进一步说明
实施例1:绿原酸组合物由绿原酸1~50克、纤维素450~499克制成1000粒。其制备方法为:将绿原酸与纤维素制粒,然后压片或灌装胶囊,每粒(片)含绿原酸1-50mg。
实施例2:绿原酸组合物由1~50克绿原酸加注射用水至1升,分装成1000支制得。其制法为:将绿原酸溶于注射用水中,加至1升,灭菌,分装。每支含1-50mg绿原酸。
实施例3:绿原酸组合物由1~50克绿原酸加注射用水至1升,分装成1000支制得。其制法为:将绿原酸溶于注射用水中,调节pH4.5-7.0,加水至1升,灭菌,分装,制成滴眼液。每支含1-50mg绿原酸。
绿原酸对醛糖还原酶抑制作用的研究
实验方法
醛糖还原酶(AR)活性测定:在NADPH的存在下,AR催化DL-甘油醛还原为甘油,同时NADPH转化为NADP,而还原态NADPH在340nm处有特征吸收,可以测定340nm处光密度的下降速率,间接测定AR的活性.在实验条件下,每min()减少0.001单位的吸光度定义为一个酶活力U。从鼠肾中提取醛糖还原酶用于筛选。NaPi缓冲液pH6.2、适量的酶液和样品的DMSO溶液,37℃保温15min,加入DL-甘油醛和NADPH,测定340nm处每minOD值的减少量A.
I=[A对照-A样品/A对照-A空白]×100%.
实验结果
绿原酸对醛糖还原酶的抑制活性的测定结果见图1,从图1可以看出,绿原酸对醛糖还原酶呈现出剂量依赖的抑制作用,其IC50为4.54μg/mL;当10.00μg/mL其抑制率为95%。
绿原酸对糖尿病鼠肾损伤的保护作用
实验方法:
试剂和仪器:NADPH Roche公司,NADP华美公司,DL2甘油醛Sigma公司,四氧嘧啶,Sigma公司,其余均为国产分析纯试。
动物处理:适应性喂养3d禁食12h,按200mg/kg体重单次腹腔注射四氧嘧啶溶液,72h后测定血糖,选取血糖在16-25mmol/L的小鼠作为实验鼠。实验分为5组:糖尿病模型组(M);模型+绿原酸低剂量组(M+CGA1,ig绿原酸10mg/kg,一天一次);模型+绿原酸中剂量组(M+CGA2,ig绿原酸20mg/kg,一天一次);模型+绿原酸高剂量组(M+CGA3,ig绿原酸40mg/kg,一天一次);模型+二甲双胍组(M+SG,ig二甲双胍25mg/kg,一天一次);连续给药30d,剪尾采血,血糖测定仪测定血糖值,取肾,称重,计算脏器指数,其中一个肾用甲醛固定,石蜡包埋,进行病理学检查,另一个肾匀浆,观察绿原酸对糖尿病鼠肾抗氧化功能的影响。
实验结果
1.绿原酸对糖尿病鼠死亡率、肾指数及血糖的影响
结果可见,绿原酸可降低糖尿病鼠死亡率、肾指数及空腹血糖,提示绿原酸对糖尿病的有益作用,结果见表1。
表1.绿原酸对糖尿病鼠死亡率、肾指数及血糖的影响
Figure C200710051341D00051
与模型组相比*P<0.05;**P<0.01
2.绿原酸对糖尿病鼠肾抗氧化功能的影响
结果可见,绿原酸可明显降低糖尿病鼠肾MDA含量,提高SOD及GSHpx酶活性,并呈剂量依赖关系,见表2。
表2.绿原酸对糖尿病鼠肾抗氧化功能的影响
Figure C200710051341D00061
与模型组相比*P<0.05;**P<0.01
3.绿原酸对糖尿病鼠肾病理学变化的影响
结果如图2所示,糖尿病鼠肾脏细胞明显水肿(模型组),绿原酸组可改善这病理变化,其中中剂量组和高剂量组效果尤其显著,未见脏细胞明显水肿;低剂量组效果与M+SG组类似,但仍可见少量脏细胞水肿;提示绿原酸对糖尿病肾病的保护作用。

Claims (5)

1.绿原酸作为醛糖还原酶抑制剂在制备抗糖尿病并发症的药中的应用。
2.根据权利要求1所述的应用,其特征是:所述抗糖尿病并发症的药为有效剂量的绿原酸与药用载体的组合物。
3.根据权利要求2所述的应用,其特征是:所述抗糖尿病并发症的药为口服制剂。
4.根据权利要求2所述的应用,其特征是:所述抗糖尿病并发症的药为注射剂。
5.根据权利要求2所述的应用,其特征是:所述抗糖尿病并发症的药为滴眼剂。
CNB2007100513411A 2007-01-23 2007-01-23 绿原酸在制备抗糖尿病并发症的药中的应用 Expired - Fee Related CN100502854C (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2007100513411A CN100502854C (zh) 2007-01-23 2007-01-23 绿原酸在制备抗糖尿病并发症的药中的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2007100513411A CN100502854C (zh) 2007-01-23 2007-01-23 绿原酸在制备抗糖尿病并发症的药中的应用

Publications (2)

Publication Number Publication Date
CN101002760A CN101002760A (zh) 2007-07-25
CN100502854C true CN100502854C (zh) 2009-06-24

Family

ID=38702289

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2007100513411A Expired - Fee Related CN100502854C (zh) 2007-01-23 2007-01-23 绿原酸在制备抗糖尿病并发症的药中的应用

Country Status (1)

Country Link
CN (1) CN100502854C (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2759903C2 (ru) * 2017-02-16 2021-11-18 Вальбьотис Фармацевтический активный ингредиент и его применение, в частности для предупреждения и лечения метаболических расстройств у людей и животных

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5274810B2 (ja) * 2007-10-18 2013-08-28 ユーシーシー上島珈琲株式会社 AGEs生成阻害剤
JP2011225455A (ja) * 2010-04-15 2011-11-10 Kao Corp Srebp抑制剤
CN104906167A (zh) * 2015-07-06 2015-09-16 四川农业大学 灰毡毛忍冬咖啡酰奎宁酸类提取物的制备方法及用途
CN115702904A (zh) * 2021-08-10 2023-02-17 成都川宇健维生物科技有限公司 包含β-烟酰胺单核苷酸和绿原酸的组合物及其应用

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
A-葡萄糖苷酶抑制剂治疗糖尿病的研究进展. 张远超,陆付耳.中国中西医结合消化杂志,第12卷第2期. 2004
A-葡萄糖苷酶抑制剂治疗糖尿病的研究进展. 张远超,陆付耳.中国中西医结合消化杂志,第12卷第2期. 2004 *
Clinical trial of Cecropia obtusifolia and Marrubiumvulgareleafextracts on blood glucose and serum lipids in type2diabetics. A. Herrera-Arellano, L. Aguilar-Santamar′a, B. Garc′a-Herna′ndez,P. Nicasio-Torres, J. Tortoriello.phytomedicine,Vol.11 No.7-8. 2004
Clinical trial of Cecropia obtusifolia and Marrubiumvulgareleafextracts on blood glucose and serum lipids in type2diabetics. A. Herrera-Arellano, L. Aguilar-Santamar′a, B. Garc′a-Herna′ndez,P. Nicasio-Torres, J. Tortoriello.phytomedicine,Vol.11 No.7-8. 2004 *
咖啡降糖活性的研究. 贾桂燕.吉林农业大学硕士学位论文. 2005
咖啡降糖活性的研究. 贾桂燕.吉林农业大学硕士学位论文. 2005 *
咖啡降血糖活性的研究. 贾桂燕.吉林农业大学硕士学位论文. 2005
咖啡降血糖活性的研究. 贾桂燕.吉林农业大学硕士学位论文. 2005 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2759903C2 (ru) * 2017-02-16 2021-11-18 Вальбьотис Фармацевтический активный ингредиент и его применение, в частности для предупреждения и лечения метаболических расстройств у людей и животных

Also Published As

Publication number Publication date
CN101002760A (zh) 2007-07-25

Similar Documents

Publication Publication Date Title
Rasouli et al. Anti-diabetic potential of plant alkaloids: Revisiting current findings and future perspectives
Gholamhoseinian et al. Inhibitory effect of methanol extract of Rosa damascena Mill. flowers on α-glucosidase activity and postprandial hyperglycemia in normal and diabetic rats
CN100502854C (zh) 绿原酸在制备抗糖尿病并发症的药中的应用
JP5763224B2 (ja) 複合生薬抽出物を含有する糖尿病性末梢神経病症の予防又は治療のための組成物
Zhang et al. A combination of grape seed‐derived procyanidins and gypenosides alleviates insulin resistance in mice and HepG2 cells
Sancheti et al. Evaluation of antidiabetic, antihyperlipidemic and antioxidant effects of Boehmeria nivea (L.) Gaudich., Urticaceae, root extract in streptozotocin-induced diabetic rats
Ardiana et al. Antidiabetic activity studies of white tea (Camellia sinensis (L.) O. Kuntze) ethanolic extracts in streptozotocin-nicotinamide induced diabetic rats
Wu et al. Regulation of catechins in uric acid metabolism disorder related human diseases
Benrahou et al. Acute toxicity, phenol content, antioxidant and postprandial anti-diabetic activity of Echinops spinosus extracts
Kalungia et al. Opuntia stricta cladode extract reduces blood glucose levels in alloxan-induced diabetic mice
Hwang et al. Anti-inflammatory effect of the hot water extract from Sasa quelpaertensis leaves
Truong et al. Antihyperglycemic and anti-type 2 diabetic activity of marine hydroquinone isolated from brown algae (Dictyopteris polypodioides)
Chewchinda et al. Antidiabetic effects of Maclura cochinchinensis (Lour.) corner heartwood extract
Rezaee-Joshogani The comparative effects of aqueous extract of walnut (Juglans regia) leaf and glibenclamide on serum glucose levels of alloxan-induced diabetic rats
US20040115285A1 (en) Method of normalizing glucose levels in blood of patients with diabetes mellitus by oral administration of proanthocyanidins containing plant extracts
Ulla et al. Supplementation of Citrus maxima fruits peel powder improves glucose intolerance and prevents oxidative stress in liver of alloxan-induced diabetic rats
Oso et al. Assessment of in vitro biological properties of aqueous extracts of Murraya koenigii L. Spreng., Thymus vulgaris L., and Ocimum gratissimum L. leaves
CN104666931B (zh) 具有护肝解酒作用的组合物及其应用
KR100473530B1 (ko) 소풍순기원 생약 복합제 추출물을 함유하는 당뇨병 예방및 치료를 위한 조성물
KR101808808B1 (ko) 벌나무 및 후박나무 추출물을 함유하는 당뇨병 또는 당뇨합병증 예방 및 치료용 조성물
CN105055399A (zh) 一种用于糖尿病防治的天然产物组合及其应用
KR101419016B1 (ko) 모시풀 추출물을 유효성분으로 함유하는 콜레스테롤 저감, 체중조절 및 비알코올성 지방간 개선용 건강기능식품
Ibrahim et al. In vivo maltase and sucrase inhibitory activities of five underutilized Nigerian edible fruits
Wang et al. Antioxidantactivity of polyphenols from Toona sinensis roem seeds and the inhibition of aldose reductase
CN103355665B (zh) 一种用于辅助降血糖的组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090624

Termination date: 20130123

CF01 Termination of patent right due to non-payment of annual fee